Skip to main content
. 2015 Mar 10;32(3):254–269. doi: 10.1007/s12325-015-0192-6

Fig. 3.

Fig. 3

Cost-effectiveness acceptability curve with MFNS versus BDNS for pediatric allergic rhinitis. The cost-effectiveness acceptability curve shows the probability of MFNS being cost-effective compared to BDNS over a wide range of WTP thresholds. This probability exceeds 99% for all WTP thresholds. BDNS beclomethasone dipropionate nasal spray, MFNS mometasone furoate nasal spray, WTP willingness-to-pay